The MPP Executive Director delivers a message on the occasion of World Health Day
In this video message, Charles Gore talks about the vital importance of demonstrating the MPP’s impact and how the organisation is making a difference to people living with HIV and hepatitis C in developing countries.
The Medicines Patent Pool signs licence with AbbVie to expand access to key hepatitis C treatment, glecaprevir/pibrentasvir
The licence will enable quality-assured manufacturers to develop and sell generic medicines containing G/P in low- and middle-income countries at affordable prices, enabling access to and treatment scale-up with the most effective pan-genotypic regimens.
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.
The MPP’s patents and licences database, MedsPaL, is a resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.
Geneva, 5 March 2019 - The Medicines Patent Pool (MPP) Governance Board has announced the appointment of Dr Mariângela Batista Galvão Simão, Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals at the World Health Organization (WHO), as a non-voting participant.
This is a unique appointment and will play a key role in supporting the development of the MPP’s mandate expansion into patented essential medicines on the WHO’s Essential Medicines List (EML) and those with strong potential for future inclusion. The expansion follows a recommendation by the WHO in 2016 that the MPP develop beyond its core remit of HIV, hepatitis C and tuberculosis, to “all disease areas, and for all patented essential medicines on the WHO EML to be licensed into the Pool.” The MPP launched a new five-year strategy in May 2018, following a feasibility study exploring an increased remit.
“This appointment not only reflects the close working relationship between the MPP and the WHO, but is also crucial for ena...
MPP statement at the 144th session of the WHO Executive Board on 29 January 2019, item 5.7.2:
Speaker: Esteban Burrone
The Medicines Patent Pool (MPP) welcomes the opportunity to comment on the report.
We note that the document mentions voluntary license agreements as one option to enhance affordability and accessibility.
Voluntary licences have played a strong role in facilitating access in other areas such as HIV and hepatitis C. Licences between the MPP and patent holders have enabled early entry of generic manufacturers and price competition in low- and middle-income countries (LMICs). As a result, health systems were able to procure effective new treatments at more affordable prices. Originators received a royalty. And millions of people gained access to treatments.
Last year, following strong support from WHO Member States, the MPP expanded its mandate to work on other patented essential medicines, which could include priority cancer medicines. We are currently working with the WHO and ot...
MPP statement at the 144th session of the WHO Executive Board on 29 January 2019, item 5.7.1:
Speaker: Elena Villanueva
The Medicines Patent Pool (MPP) welcomes the WHO Roadmap and the inclusion of public health-oriented licensing agreements as a way to foster access to health products.
The MPP, established by Unitaid, has become the main driver of public health-oriented licensing agreements for access to medicines in low- and middle-income countries (LMICs). It has already enabled over 100 countries to get faster access to new HIV and hepatitis C treatments at affordable prices and in suitable formulations.
We note the Roadmap proposes as a deliverable support for the expansion of the MPP to other patented essential medicines through identification of potential products for licensing. As part of this process, earlier this week, within the framework of the WHO Technical Consultation on the Essential Medicines Lists (EMLs), the MPP consulted with a number of Member States on which essential medici...
“I am honoured to be invited to represent the WHO on the MPP’s Governance Board. Access to essential medicines is fundamental to the ability of everyone to achieve the highest attainable standard of health and core to the Sustainable...”
Unable to load twitter timeline, please allow cookie